Skip to main
CRBP

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. presents a positive outlook as its development pipeline features CRB-701, which is viewed favorably by key opinion leaders (KOLs) due to its potential to improve patient survival rates and offer a superior safety profile compared to existing treatments. The promising early weight loss signals from CRB-913, alongside an “all comers” trial design that enhances enrollment speed in challenging indications like head and neck squamous cell carcinoma (HNSCC), further strengthens its competitive position. With a differentiated approach in safety and efficacy metrics, particularly for CRB-701, the company appears well-equipped to meet regulatory timelines and capitalize on expanding market opportunities in oncology and obesity treatments.

Bears say

Corbus Pharmaceuticals Holdings Inc. faces significant risks that contribute to a negative outlook on its stock. The company’s drug candidates, CRB-701 and CRB-913, may not achieve the desired efficacy or safety, with potential delays in regulatory approval further exacerbating these concerns. Additionally, Corbus's pipeline assets are exposed to competitive pressures from existing and future therapies, which may hinder their commercial viability and impact overall financial performance.

CRBP has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 4 analysts, CRBP has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.